Psilocybin has accumulated the strongest evidence base among psychedelics for psychiatric indications. Phase 2 and Phase 3 trials in treatment-resistant depression, major depressive disorder, end-of-life psychological distress in advanced cancer, and alcohol use disorder have produced meaningful efficacy signals with response rates in the 50–80% range and sustained response at 6–12 months in substantial subsets of treated patients. The 2026 clinical landscape includes active FDA review pathways, state-level supervised access in some jurisdictions, and an evolving infrastructure of trained facilitators and protocols.
The TRD evidence is the most developed. Compass Pathways' COMP360 psilocybin Phase 2 trial in TRD showed substantial response and remission rates at single 25mg dose with psychological support; the Phase 3 program followed with similar efficacy. Usona Institute's USONA-001 program for MDD has produced parallel evidence. Response rates in TRD trials typically run 50–70% at week 3, with 30–50% sustained response at 6 months — substantially better than historical TRD response rates with conventional treatment. The mechanism (rapid plasticity, integration psychotherapy) accounts for the durability of response that ongoing pharmacotherapy does not require.
The end-of-life distress indication has long-standing evidence. Roland Griffiths' work at Johns Hopkins and Charles Grob's parallel work demonstrated substantial reduction in anxiety and depression in patients with advanced cancer, with effects sustained months after a single dose. The mechanism appears to involve mystical-type experiences (assessed by the Mystical Experience Questionnaire) which mediate much of the therapeutic effect. The end-of-life indication is one of the most ethically and practically compelling cases for psychedelic-assisted treatment — patients with limited time benefit from rapid, durable change that conventional treatment frequently cannot produce.
The alcohol use disorder evidence is emerging. Bogenschutz and colleagues' work has demonstrated meaningful reduction in heavy drinking days and other AUD outcomes following psilocybin-assisted treatment. The mechanism may involve insight into addiction patterns, perspective shifts on substance use, and psychological flexibility for behavior change. AUD is one of the conditions where the integration psychotherapy frame fits particularly well — the acute experience produces openings that the integration work consolidates into sustained behavior change.
The access landscape varies substantially. Clinical trials remain the most reliable pathway in the US — trial registries (clinicaltrials.gov) list active protocols. Oregon Measure 109 created a state-level supervised psilocybin access program effective 2023; Colorado Proposition 122 has done similar; other states are following. These programs provide non-medical supervised access for adults regardless of diagnosis. FDA approval for medical use remains pending; the pathway through the 2024–2026 period has been complex. International access (Netherlands, Jamaica, others) is available for patients with means to travel. The advice for individual patients depends on their jurisdiction, severity, and resources.
The clinical integration with conventional treatment. Psilocybin-assisted treatment is not standalone — it requires preparation work with a trained therapist (typically 2–4 sessions), the dosing session itself with trained facilitators, and integration psychotherapy in the weeks following (typically 3–8 sessions). Medication adjustments are part of preparation — SSRIs and SNRIs are typically tapered 2–4 weeks before the session due to receptor downregulation effects that may blunt psilocybin response. The conventional treatment context continues — the patient on antidepressant for years considering psilocybin treatment is doing both as part of an integrated approach, not abandoning conventional care for the psychedelic. The discipline is to recognize psilocybin as a legitimate clinical option with developing evidence and access, to integrate it thoughtfully into broader treatment, and to maintain the longitudinal clinical relationship that supports the work.